Ethyl 2-cyclobutylacetate

Catalog No.: 
ACDMZX820
CAS No.: 
38353-27-4
Molecular Formula: 
C8H14O2
Molecular Weight: 
142.20
Ethyl 2-cyclobutylacetate structure diagram
Pack SizePurityList PriceYour PriceGlobal StockUS StockQuantity
1g96%$128.00In stockIn stock
5g96%$514.00In stockIn stock
10g96%$977.00In stockIn stock
25g96%$1615.00InquiryInquiry

Products of AiFChem are all designed for scientific research only. Under no circumstances do we provide products or services for animal or personal utilization.

Product Information

Product NameEthyl 2-cyclobutylacetate
IUPAC Nameethyl 2-cyclobutylacetate
MDL No.MFCD09953134
Molecular FormulaC8H14O2
Molecular Weight142.20
SMILESCCOC(=O)CC1CCC1
InChI KeyJPXIQOLOFKDUFB-UHFFFAOYSA-N
SynonymSB12962 | Ethyl 2-cyclobutylacetate | Cyclobutyl-acetic acid ethyl ester | DTXSID90558888 | ETHYL2-CYCLOBUTYLACETATE | AS-42083 | CS-D0101 | MFCD09953134 | JPXIQOLOFKDUFB-UHFFFAOYSA-N | SY240747 | A873858 | Ethyl cyclobutylacetate | FT-0749378 | SCHEMBL18
CAS No.38353-27-4
PubChem CID14322004

Safety Data

Pictogram
Harmful or irritant
Signal Word
Warning
Hazard Statement(s)
H302
Precautionary Statement(s)
P280-P305+P351+P338

Synthetic Route by SureRoute

1. ACDMZX820 Molecular Building Block Synthetic Route

Source: SureRouteAuthor: aifchem

  1. ACJWGY395 route compound structure diagram
    ACJWGY39527741-65-7In Stock
  2. Then
  3. ACDMZX820 route product structure diagram
    ACDMZX82038353-27-4In Stock
Inquiry

2. ACDMZX820 Molecular Building Block Synthetic Route

Source: SureRouteAuthor: aifchem

  1. ACTRMX927 route compound structure diagram
    ACTRMX927555-75-9
  2. Plus
  3. ACROUX812 route compound structure diagram
    ACROUX8126540-33-6In Stock
  4. Then
  5. ACDMZX820 route product structure diagram
    ACDMZX82038353-27-4In Stock
Inquiry

3. ACDMZX820 Molecular Building Block Synthetic Route

Source: SureRouteAuthor: aifchem

  1. reactant_1 route compound structure diagram
    --
  2. Then
  3. ACDMZX820 route product structure diagram
    ACDMZX82038353-27-4In Stock
Inquiry

Comments (0)